| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30010584 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30015669 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30007413 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30002958 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30012523 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30007414 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30002959 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30007415 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30007416 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
| TVIS30002960 | HIV | ENSG00000130816.17 | protein_coding | DNMT1 | Yes | No | 1786 | I6L9H2 P26358 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DNMT1 |
|---|---|
| DrugBank ID | DB00928 |
| Drug Name | Azacitidine |
| Target ID | BE0000892 |
| UniProt ID | P26358 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 15793220; 19589026; 14585280; 17612710; 12011120; 16341239; 11700387; 18627335; 20126405; 2443243 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R: FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005 Mar;10(3):176-82.@@Cataldo VD, Cortes J, Quintas-Cardama A: Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. doi: 10.1586/era.09.61.@@Leone G, Voso MT, Teofili L, Lubbert M: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003 Oct;109(1):89-102.@@Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007 Jun;43(6):395-422.@@Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15;20(10):2429-40.@@Fenaux P: Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S36-44.@@Silverman LR: Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001;6 Suppl 5:8-14.@@O'Dwyer K, Maslak P: Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981 .@@Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010 Feb 2;5(2):e9001. doi: 10.1371/journal.pone.0009001.@@Glover AB, Leyland-Jones B: Biochemistry of azacitidine: a review. Cancer Treat Rep. 1987 Oct;71(10):959-64. |
| Groups | Approved; Investigational |
| Direct Classification | Glycosylamines |
| SMILES | NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O |
| Pathways | |
| PharmGKB | PA451996 |
| ChEMBL | CHEMBL1489 |
